The Oncology Institute Stock Today
| TOIIW Stock | USD 0.02 0.0001 0.43% |
PerformanceGood
| Odds Of DistressBelow Average
|
Oncology Institute is selling for under 0.023 as of the 21st of March 2025; that is 0.43 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.0228. Oncology Institute has about a 43 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. The company was founded in 2007 and is based in Cerritos, California. Oncology Institute operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. More on The Oncology Institute
Moving against Oncology Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Oncology Stock Highlights
| CEO Director | FACHE MBA |
| Thematic Idea | Healthcare (View all Themes) |
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, Healthcare, Health Care, Health Care Equipment & Supplies, Medical Care Facilities, Healthcare (View all Sectors) |
The Oncology Institute (TOIIW) is traded on NASDAQ Exchange in USA. It is located in 18000 Studebaker Road, Cerritos, CA, United States, 90703 and employs 800 people. Oncology Institute is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company classifies itself under Health Care Equipment & Supplies sector and is part of Health Care industry.
The Oncology Institute has accumulated about 15.17 M in cash with (36.31 M) of positive cash flow from operations.
Check Oncology Institute Probability Of Bankruptcy
The Oncology Institute Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Oncology Institute market risk premium is the additional return an investor will receive from holding Oncology Institute long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.1634 | |||
| Jensen Alpha | 3.95 | |||
| Total Risk Alpha | 5.6 | |||
| Sortino Ratio | 0.219 |
Oncology Stock Against Markets
Oncology Institute Corporate Management
| FACHE MD | Chief Officer | Profile | |
| Mark Esq | General Counsel | Profile | |
| Rob Carter | Senior Finance | Profile | |
| Laura Szitar | Chief Officer | Profile | |
| Richard Barasch | Executive Board | Profile | |
| Jeremy MBA | Chief Officer | Profile |
Additional Tools for Oncology Stock Analysis
When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.